Request Demo

Last update 25 Jul 2026

Aldoxorubicin Hydrochloride

Last update 25 Jul 2026

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Aldoxorubicin, Aldoxorubicin Hydrochloride (USAN), DOXO-EMCH

+ [2]

Target

DNA x Top II

Action

inhibitors

Mechanism

DNA intercalators, Top II inhibitors(Topoisomerase II inhibitors)

Therapeutic Areas

NeoplasmsInfectious Diseases

Active Indication

SarcomaTuberculosis

Inactive Indication

Acquired Immunodeficiency SyndromeAdvanced Malignant Solid NeoplasmAdvanced Pancreatic Ductal Adenocarcinoma+ [19]

Originator Organization

Bristol Myers Squibb Co.

Active Organization

Tsinghua University

Bristol Myers Squibb Co.

LadRx Corp.

Inactive Organization

ImmunityBio, Inc.

NantKwest, Inc.

Innovive Pharmaceuticals, Inc.

License Organization

LadRx Corporation

ImmunityBio, Inc.

Drug Highest PhasePhase 3

First Approval Date-

RegulationOrphan Drug (United States)

Structure/Sequence

Molecular FormulaC37H43ClN4O13

InChIKeyNGKHWQPYPXRQTM-UKFSEGPMSA-N

CAS Registry1361563-03-2

Clinical Trials associated with Aldoxorubicin Hydrochloride

NCT04390399

/ Active, not recruitingPhase 2

Open-label, Randomized, Comparative Phase 2 Study of Combination Immunotherapy Plus Standard-of-care Chemotherapy Versus Standard-of-care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer

This is a phase 2, three-cohort (2 randomized and 1 single-arm), open-label study to evaluate the comparative efficacy and overall safety of standard-of-care chemotherapy versus standard-of-care chemotherapy in combination with aldoxorubicin HCl, N-803, and PD-L1 t-haNK in subjects with locally advanced or metastatic pancreatic cancer. Each treatment setting (ie, first line maintenance, second line, or third line or greater) will be evaluated independently as a separate cohort.

Start Date21 Jul 2020

Sponsor / Collaborator

ImmunityBio, Inc.

NCT03563157

/ TerminatedPhase 1/2

NANT Colorectal Cancer (CRC) Vaccine: A Phase 1b/2 Trial of the NANT CRC Vaccine vs Regorafenib in Subjects With Metastatic CRC Who Have Been Previously Treated With Standard-of-Care Therapy

QUILT 3.071 NANT Colorectal Cancer (CRC) Vaccine: This is a Phase 1b/2 study investigating the effect of NANT CRC vaccine vs regorafenib in subjects with CRC who were previously treated with SOC.

Start Date28 Sep 2018

Sponsor / Collaborator

ImmunityBio, Inc.

NCT03554109

/ WithdrawnPhase 2

An Open-Label Randomized Phase 2 Trial Of The NANT NEOADJUVANT Triple-Negative Breast Cancer (TNBC) VACCINE VS Standard-Of-Care For The Neoadjuvant Treatment Of Subjects With TNBC

This is a randomized open-label phase 2 study to evaluate the efficacy and safety (as assessed by pCR) of the NANT Neoadjuvant TNBC Vaccine regimen (experimental arm) compared to the SoC dose-dense regimen of doxorubicin/cyclophosphamide followed by paclitaxel (control arm).

Start Date01 Sep 2018

Sponsor / Collaborator

ImmunityBio, Inc.

100 Clinical Results associated with Aldoxorubicin Hydrochloride

100 Translational Medicine associated with Aldoxorubicin Hydrochloride

100 Patents (Medical) associated with Aldoxorubicin Hydrochloride

Literatures (Medical) associated with Aldoxorubicin Hydrochloride

02 Jun 2025·ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

High‐Fidelity In Vitro Packaging of Diverse Synthetic Cargo into Encapsulin Protein Cages

Article

Author: Taylor N. Szyszka ; Alex Loustau ; Tiancheng Huang ; Claire Rennie ; Andrew Care ; Lachlan S. R. Adamson ; Yu Heng Lau ; Reginald Young ; Rezwan Siddiquee

Abstract:

Cargo‐filled protein cages are powerful tools in biotechnology with demonstrated potential as catalytic nanoreactors and vehicles for targeted drug delivery. While endogenous biomolecules can be packaged into protein cages during their expression and self‐assembly inside cells, synthetic cargo molecules are typically incompatible with live cells and must be packaged in vitro. Here, we report a fusion‐based in vitro assembly method for packaging diverse synthetic cargo into encapsulin protein cages that outperforms standard in cellulo assembly, producing cages with superior uniformity and thermal stability. Fluorescent dyes, proteins and cytotoxic drug molecules can all be selectively packaged with high efficiency via a peptide‐mediated targeting process. The exceptional fidelity and broad compatibility of our in vitro assembly platform enables generalisable access to cargo‐filled protein cages that host novel synthetic functionality for diverse biotechnological applications.

01 Jun 2025·Rare Tumors

Efficacy and cardiac safety of aldoxorubicin in metastatic solitary fibrous tumour

Article

Author: Jones, Robin L ; Benson, Charlotte ; Thway, Khin ; Vosylius, Karolina ; Napolitano, Andrea ; Christien Li, Ka Hou ; Fotiadis, Nicos ; Price, Gareth

Solitary fibrous tumours (SFT) are very rare mesenchymal neoplasms. While surgery remains a standard treatment for localised disease, effective and long term treatment options for metastatic disease are lacking, making the use of aldoxorubicin a novel and promising systemic treatment in SFTs. We present a 30-year-old male who underwent surgical resection for a solitary fibrous tumour of the right leg. Postoperative imaging revealed metastatic disease in the liver and left upper quadrant. He was initially treated with pazopanib but experienced disease progression after 24 weeks. The patient was then enrolled on a phase III trial evaluating aldoxorubicin for advanced soft tissue sarcomas and received 350 mg/m 2 (260 mg/m 2 doxorubicin equivalent) intravenously every 21 days, cumulative dose being 9100 mg/m 2 . Treatment was well tolerated, with manageable toxicities including alopecia, leukopenia, mucositis, and grade 3 neutropenia requiring G-CSF support. Notably, serial echocardiograms showed no evidence of cardiotoxicity, with a preserved ejection fraction (56–65%). He completed 26 cycles with stable disease, followed by a 7-month treatment break before receiving compassionate-use aldoxorubicin. Disease stability persisted for 6 months until progression, which was treated with radiotherapy. Three months later, systemic progression led to treatment discontinuation. This case illustrates the favourable cardiac safety profile of aldoxorubicin and efficacy in solitary fibrous tumours.

01 May 2025·INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES

EGFR Affibody and PEG functionalized protein nanoparticles: Sustaining targeting and macrophage evasion

Article

Author: Murthy, Niren ; Kang, Sebyung ; Jun, Heejin ; Kim, Hansol ; Zhao, Sheng ; Jang, Seonhye ; Eom, Soomin

When nanoparticles are introduced into a biological environment, serum proteins rapidly attach to their surfaces, leading to opsonization and subsequent rapid clearance by the immune system. In this study, we functionalized protein nanoparticles with PEG to impart stealth properties, aiming to reduce immune recognition. By incorporating EGFRAfb, we conferred targeting capabilities to the PEGylated protein nanoparticles, demonstrating their ability to specifically bind to target cells even after PEGylation. Additionally, the stealth effect conferred by PEGylation effectively prevented phagocytosis by macrophages. Taken together, these results indicate that PEGylated protein nanoparticles not only exhibit increased in vivo half-life due to reduced opsonization but also maintain cell-specific targeting capabilities.

News (Medical) associated with Aldoxorubicin Hydrochloride

27 May 2026

·www.biospace.com

Gemini Therapeutics Announces ASCO 2026 Analyses Supporting Aldoxorubicin’s Tumor-Targeted Delivery and Cardiac-Safety Profile

Integrated analyses show higher tumor exposure than doxorubicin and better preservation of cardiac function in randomized soft tissue sarcoma studies despite approximately 3.5-fold higher cumulative doxorubicin-equivalent exposure SAN FRANCISCO--(BUSINESS WIRE)-- #ASCO --Gemini Therapeutics, Inc., a privately held biotechnology company focused on advancing aldoxorubicin for patients with cancer, today announced two aldoxorubicin abstracts at the 2026 American Society of Clinical Oncology Annual Meeting. The analyses examine complementary elements of aldoxorubicin’s development rationale: tumor-targeted anthracycline delivery and cardiac safety at cumulative doxorubicin-equivalent exposures that are difficult to achieve with conventional doxorubicin. Aldoxorubicin is an investigational albumin-binding prodrug of doxorubicin designed to bind endogenous albumin after intravenous administration, limit freely circulating doxorubicin, and release native doxorubicin in acidic tumor-associated and intracellular compartments. This exposure pro intended to exploit albumin transport into tumors while reducing systemic exposure patterns associated with conventional doxorubicin, including exposure to cardiotoxic metabolites such as doxorubicinol. “Doxorubicin remains one of oncology’s most important cytotoxic therapies, but its use is constrained by tumor-delivery limitations and cumulative cardiotoxicity,” said Diego Rey, PhD, Chief Executive Officer of Gemini Therapeutics. “These ASCO analyses support a focused re-evaluation of aldoxorubicin from two complementary directions: higher tumor exposure than conventional doxorubicin and better preservation of cardiac function despite substantially higher cumulative doxorubicin-equivalent exposure. The lower systemic doxorubicinol burden provides an important mechanistic bridge between aldoxorubicin’s albumin-bound design and the cardiac-safety findings observed in randomized soft tissue sarcoma studies. Together, these findings support the rationale that a better exposure-toxicity tradeoff could make meaningful anthracycline exposure feasible for more patients and in more tumor settings where conventional doxorubicin has been limited by delivery or cumulative cardiotoxicity.” The first ASCO analysis, a poster presentation titled “Cardiac safety of aldoxorubicin compared to doxorubicin: Integrated results from two randomized studies in advanced soft tissue sarcoma,” evaluated cardiac safety across two randomized soft tissue sarcoma studies. The pooled analysis included 383 patients in the aldoxorubicin-versus-doxorubicin cardiac safety population: 296 treated with aldoxorubicin and 87 treated with doxorubicin comparator. In the analysis, patients treated with aldoxorubicin received approximately 3.5-fold higher cumulative doxorubicin-equivalent exposure than patients treated with doxorubicin. Despite this higher exposure, aldoxorubicin was associated with smaller mean declines in left ventricular ejection fraction, fewer patients reaching selected on-treatment LVEF thresholds, and fewer prespecified heart-failure-related treatment-emergent adverse events. Mechanistically, the cardiac-safety findings are supported by pharmacokinetic data showing that aldoxorubicin plasma exposure is dominated by albumin-bound doxorubicin, with substantially lower free doxorubicin and doxorubicinol concentrations. In Phase 1 aldoxorubicin data, the doxorubicinol-to-free-doxorubicin exposure ratio was approximately 5% to 6%, compared with approximately 40% to 60% reported for conventional doxorubicin, consistent with lower systemic exposure to this cardiotoxic metabolite. Lowest on-treatment mean LVEF change from baseline was -3.17 percentage points with aldoxorubicin versus -5.77 percentage points with doxorubicin . On-treatment LVEF below 50% occurred in 3.8% of aldoxorubicin-treated patients versus 9.0% of doxorubicin-treated patients; on-treatment LVEF below 45% occurred in 1.1% versus 3.8% , respectively. Prespecified heart-failure-related treatment-emergent adverse events occurred in 3.0% of aldoxorubicin-treated patients versus 6.9% of doxorubicin-treated patients. The second ASCO analysis, titled “Tumor Delivery and Exposure of Aldoxorubicin Compared with Doxorubicin: Integrated Clinical and Preclinical Analysis,” evaluated human tumor-biopsy pharmacokinetic data and preclinical biodistribution data comparing aldoxorubicin with doxorubicin. In human Kaposi’s sarcoma tumor biopsies, aldoxorubicin was detected in all sampled lesions and increased with dose. When normalized for dose and adjusted for potency, aldoxorubicin delivered up to approximately 10-fold higher intratumoral doxorubicin-equivalent exposure than conventional doxorubicin. Aldoxorubicin has previously been evaluated across a broad clinical development and early access program involving more than 750 aldoxorubicin-exposed patients. Gemini acquired the aldoxorubicin program from LadRx Corporation in 2025 and is advancing it under a focused, evidence-guided development strategy informed by the substantial clinical, pharmacokinetic, and safety data generated to date. ASCO 2026 Abstract Details Poster Presentation Abstract #: 11565 Poster Board #: 355 Date and Time: June 1, 2026, 1:30 PM-4:30 PM CDT Title: Cardiac safety of aldoxorubicin compared to doxorubicin: Integrated results from two randomized studies in advanced soft tissue sarcoma First Author: Philip Sager, MD Presenter: Diego Rey, PhD Citation: J Clin Oncol 44, 2026 (suppl 16; abstr 11565) DOI: 10.1200/JCO.2026.44.16_suppl.11565 Publication Only Abstract Abstract #: e15134 Title: Tumor delivery and exposure of aldoxorubicin compared with doxorubicin: Integrated clinical and preclinical analysis First Author: Joyce James, PhD Citation: J Clin Oncol 44, 2026 (suppl 16; abstr e15134) DOI: 10.1200/JCO.2026.44.16_suppl.e15134 About Aldoxorubicin Aldoxorubicin, also known historically as INNO-206 or DOXO-EMCH, is an investigational albumin-binding prodrug of doxorubicin. Aldoxorubicin is designed to bind endogenous serum albumin after intravenous administration and release native doxorubicin under acidic conditions found in tumor-associated and intracellular compartments. The intended therapeutic rationale is to alter the exposure pattern of doxorubicin by increasing tumor-directed anthracycline delivery while reducing systemic exposure patterns associated with conventional doxorubicin. Aldoxorubicin is investigational and has not been approved by the U.S. Food and Drug Administration. Safety and effectiveness have not been established. About Gemini Therapeutics Gemini Therapeutics is a newly formed privately held biotechnology company focused on advancing aldoxorubicin for patients with cancer. Gemini was founded with a patient-centered mission to develop therapies that preserve the anti-cancer potential of foundational oncology drugs while addressing the limitations that prevent patients from receiving or continuing those therapies. The company is focused on evidence-guided development strategies in settings where aldoxorubicin’s tumor-delivery and usable anthracycline-exposure pro matter most. Forward-Looking Statements This press release contains forward-looking statements, including statements regarding the potential development rationale, potential clinical utility, future development plans, regulatory strategy, and possible benefits of aldoxorubicin. These statements are based on Gemini Therapeutics’ current expectations and involve risks and uncertainties that could cause actual results to differ materially. Aldoxorubicin is investigational, and no regulatory authority has approved aldoxorubicin for any indication. The results described in prior or integrated analyses may not predict results in future studies. Gemini Therapeutics undertakes no obligation to update forward-looking statements except as required by applicable law. Contacts Gemini Therapeutics, Inc. info@geminithera.com

Clinical ResultASCOPhase 1

12 Dec 2024

·www.businesswire.com

LadRx Planning NDA Submission under 505(b)(2) for Aldoxorubicin and Other Updates

LOS ANGELES--( BUSINESS WIRE )--LadRx Corporation (OTCQB: LADX) (“LadRx” or the “Company”), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, is pleased to announce that the Company is restarting a process to seek marketing approval of aldoxorubicin under the provisions of the FDA’s Section 505(b)(2). The 505(b)(2) pathway is designed for a new drug composition whose active ingredient is the same active ingredient as a drug previously approved by the US Food and Drug Administration (FDA). Given that the active component of the tumor-targeted drug aldoxorubicin is the already-marketed drug doxorubicin, the 505(b)(2) pathway is available for aldoxorubicin, and greatly reduces the regulatory burden of getting aldoxorubicin to the market by relying on the non-clinical and clinical data history of doxorubicin to demonstrate efficacy and safety. Additionally, the market exclusivity awarded to drugs that have received orphan designation for certain rare diseases, as is the case for aldoxorubicin, is available for drugs approved through the 505(b)(2) process for new drugs. In 2017, following discussions between LadRx and the FDA (see announcement on June 8, 2017), LadRx initiated work to assemble the data to support a marketing approval under section 505(b)(2) for aldoxorubicin for the treatment of soft tissue sarcoma. While this work was ongoing, LadRx entered a license agreement with Nantcell, Inc. ( see announcement on June 8, 2017), which stopped the 505(b)(2) process. With the termination of the aldoxorubicin license agreement between LadRx and NantCell in June 2024, LadRx regained control of aldoxorubicin. LadRx has restarted the 505(b)(2) process for obtaining marketing authorization for aldoxorubicin for the treatment of soft-tissue sarcoma. LadRx expects this process to encompass some bridging studies in animals to bridge the data between doxorubicin and aldoxorubicin, but does not expect to conduct additional human clinical studies. Subject to receiving additional funding, LadRx plans to request a pre-NDA meeting with the FDA mid-2025 to confirm the requirements that were discussed between the Company and the FDA prior to the out-licensing of aldoxorubicin in 2017. Completion of the NDA-related activities and subsequent marketing application and approval are dependent on agreement by the FDA, and on gaining additional funding, neither of which can be guaranteed. Stephen Snowdy, PhD, CEO of LadRx commented, “Patients who are suffering the burden of cancer deserve the best treatments science can offer. In soft tissue sarcoma in particular, oncologists have shared with us the significant unmet need that still exists for this patient population. We feel that aldoxorubicin will add a valuable therapy to oncologists’ armory. We are encouraged by the conversations that have taken place between LadRx and the FDA, and we feel that the planned 505(b)(2) pathway to approval is appropriate, and if successful, would represent a rapid and low-cost path to market for aldoxorubicin that requires no further human clinical study. Combined with our clinic-ready tumor-targeted drug LADR-7, and several pre-clinical assets, we have a full pipeline of opportunity to potentially help those suffering from solid tumors. We believe strongly in the potential of our chemotherapies, and are continuing to evaluate financing and strategic alternatives to see these therapies through to the patients who need them.” LadRx is also pleased to announce that it has received a $1 million milestone payment related to arimoclomol. LadRx is currently evaluating pathways to funding its activities, which may include, but are not limited to, mergers, out-licensing, and equity and non-equity financings. About Aldoxorubicin Aldoxorubicin is a rationally engineered cytotoxic which combines doxorubicin, a widely used chemotherapeutic agent, with a novel linker molecule that binds in inactive form to circulating albumin, the most abundant protein in the bloodstream. Protein-hungry tumors concentrate albumin, which facilitates the delivery of the chemotoxin to tumor sites. In the acidic environment of the tumor, but not the neutral environment of healthy tissues, doxorubicin is released in active form. Typically, doxorubicin is delivered systemically and is highly toxic, which limits its dose to a level below its maximum therapeutic benefit. Doxorubicin also is associated with many side effects, especially the potential for damage to heart muscle at cumulative doses greater than 450 mg/m2. Using this acid-sensitive linker technology, aldoxorubicin delivers greater doses of doxorubicin (3 ½ to 4 times). To date, there has been no evidence of clinically significant effects of aldoxorubicin on heart muscle, even at cumulative doses of the drug well in excess of 5,000 mg/m2. Aldoxorubicin is the first-ever single agent to show superiority over doxorubicin in a randomized clinical trial in first-line soft tissue sarcoma. About Soft Tissue Sarcoma Soft tissue sarcoma is a cancer occurring in muscle, fat, blood vessels, tendons, fibrous tissues and connective tissue. It can arise anywhere in the body at any age. STS remains a high unmet medical need because of the difficulty in treating the more than 50 types of this aggressive cancer. According to the American Cancer Society, in 2024 more than more than 13,000 new cases are expected to be diagnosed in the U.S. and approximately 5,200 Americans are expected to die from this disease. Globally, in 2021, there were approximately 96,000 people diagnosed with soft tissue sarcoma (Global Burden of Disease 2021). In addition, there are approximately 167,000 people in the US living with soft tissue sarcoma ( www.cancer.gov , data from 2022). Forward-Looking Statements This press release may contain certain statements relating to future results which are forward-looking statements, including, without limitation, whether the company will be able to secure new financing to fund its operations and clinical programs, or receive clearance from the FDA of its 505(b)(2) application for Aldoxorubicin. These statements are not historical facts, but instead represent only LadRx’s belief regarding future events, many of which, by their nature, are inherently uncertain and outside of LadRx’s control. Such statements involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements; and other risks and uncertainties described in the most recent annual and quarterly reports filed by LadRx with the SEC, including disclosures under the heading “Risk Factors,” and current reports filed since the date of the LadRx’s most recent annual report. All forward-looking statements are based upon information available to LadRx on the date the statements are first published. LadRx undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. About LadRx LadRx Corporation (OTCQB: LADX) is a biopharmaceutical company developing new therapeutics to treat patients with cancer. LadRx Corporation’s website is www.ladrxcorp.com .

License out/inOrphan DrugNDA

04 Jun 2024

·www.biospace.com

LadRx and ImmunityBio Mutually Agree to Terminate Aldoxorubicin License

Aldoxorubicin Returns to LadRx LOS ANGELES -- (BUSINESS WIRE)-- LadRx Corporation (OTCQB: LADX) (“LadRx” or the “Company”), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, is pleased to announce that the Company and NantCell, Inc. (“NantCell”), together with NantCell’s parent company ImmunityBio, Inc. (“ImmunityBio”), have agreed to a mutual termination of the license of aldoxorubicin entered into in 2017. With the termination of the license agreement between LadRx and NantCell, LadRx regains control of aldoxorubicin. In 2023, LadRx transferred the royalty and milestone rights of arimoclomol and aldoxorubicin to XOMA Corporation (NASDAQ: XOMA) (“XOMA”) in exchange for $5 million in upfront gross proceeds, up to an additional $2 million for milestones related to arimoclomol and $5 million for milestones related to aldoxorubicin. XOMA consented to the mutual termination of the LadRx-NantCell agreement in order to facilitate the return of the program to LadRx. In parallel, LadRx and XOMA have amended their 2023 Royalty Purchase Agreement to provide XOMA with a low-single-digit synthetic royalty on aldoxorubicin and a mid-single-digit percentage of any economics derived by LadRx from future out-license agreements related to aldoxorubicin. The agreement between LadRx and XOMA regarding future royalties and milestones associated with arimoclomol is not affected by the termination of the aldoxorubicin license between LadRx and NantCell. Stephen Snowdy, PhD, CEO of LadRx commented, “We are excited to have aldoxorubicin back in-house. Aldoxorubicin is the first LADR-based drug to reach the clinic and was shown in multiple clinical studies to have lower cardiotoxicity compared to doxorubicin while showing promise of efficacy in a Phase II trial in advanced soft tissue sarcoma. Aldoxorubicin also proved the premise of LADR-based drugs that targeting chemotoxins via the LADR backbone allows for several-fold higher dosing of chemotherapeutic drugs.” Dr. Snowdy continued, “We congratulate ImmunityBio on their recent successes with their immunity-based products and certainly understand their going-forward focus on those modalities. Over the coming months, we will be reviewing the pre-clinical and clinical data for aldoxorubicin and plotting a path forward for its continued clinical development. Meanwhile, we continue to march LADR-7 towards the clinic and remain on track for filing an IND application for LADR-7 in the third or fourth quarter of 2024.” Forward-Looking Statements This press release may contain certain statements relating to future results which are forward-looking statements, including whether the company’s strategic review will be successful and whether the stock split will help the company be more successful in evaluating strategic alternatives. These statements are not historical facts, but instead represent only LadRx’s belief regarding future events, many of which, by their nature, are inherently uncertain and outside of LadRx’s control. Such statements involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements; and other risks and uncertainties described in the most recent annual and quarterly reports filed by LadRx with the SEC, including disclosures under the heading “Risk Factors,” and current reports filed since the date of the LadRx’s most recent annual report. All forward-looking statements are based upon information available to LadRx on the date the statements are first published. LadRx undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. About LadRx LadRx Corporation (OTCQB: LADX) is a biopharmaceutical company developing new therapeutics to treat patients with cancer. LadRx Corporation’s website is . View source version on businesswire.com: Contacts Longacre Square Partners Greg Marose / Charlotte Kiaie ladrx@longacresquare.com Source: LadRx Corporation View this news release online at:

License out/inPhase 2

100 Deals associated with Aldoxorubicin Hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
D10384	Aldoxorubicin Hydrochloride	-	DB06013

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Soft Tissue Sarcoma	Phase 3	United States	ImmunityBio, Inc.	01 Jan 2014
Soft Tissue Sarcoma	Phase 3	Australia	ImmunityBio, Inc.	01 Jan 2014
Soft Tissue Sarcoma	Phase 3	Canada	ImmunityBio, Inc.	01 Jan 2014
Soft Tissue Sarcoma	Phase 3	Chile	ImmunityBio, Inc.	01 Jan 2014
Soft Tissue Sarcoma	Phase 3	Denmark	ImmunityBio, Inc.	01 Jan 2014
Soft Tissue Sarcoma	Phase 3	France	ImmunityBio, Inc.	01 Jan 2014
Soft Tissue Sarcoma	Phase 3	Hungary	ImmunityBio, Inc.	01 Jan 2014
Soft Tissue Sarcoma	Phase 3	Israel	ImmunityBio, Inc.	01 Jan 2014
Soft Tissue Sarcoma	Phase 3	Italy	ImmunityBio, Inc.	01 Jan 2014
Soft Tissue Sarcoma	Phase 3	Netherlands	ImmunityBio, Inc.	01 Jan 2014

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01514188 (INNO-206-STS-P2-01, ASCO2026)	Phase 2/3	Locally Advanced Soft Tissue Sarcoma	383	aldoxorubicin	jzxjyxdizu(jcfeicsqyd) = tmunicmiya aejumqarvr (ivvjuyaqou )	Positive	29 May 2026
				doxorubicin	jzxjyxdizu(jcfeicsqyd) = ijvwurvacd aejumqarvr (ivvjuyaqou )
NCT03563157 (CTgov)	Phase 1/2	Metastatic Colorectal Carcinoma	2	SBRT+Aldoxorubicin Hydrochloride+GI-6301+GI-4000+ETBX-061+Cetuximab+ETBX-051+ETBX-011+5-fluorouracil+ALT-803+ETBX-021+Nab-paclitaxel+Cyclophosphamide+Avelumab+haNK+Leucovorin+GI-6207+Regorafenib+oxaliplatin+Capecitabine (NANT Colorectal Cancer (CRC) Vaccine)	cvjwtvfxbt = ozeycrtmqo ttvcmpxcig (kedlnwpsgt, zzsjkqyvfm - teiontowny) View more	-	11 Dec 2024
				Regorafenib (Regorafenib)	ldrbswqzdl(wrwejphals) = ghchlywgji qwrryfhult (qwdyonqhrt, smjufdrmsr - mnwzaidmlp) View more
NCT02200757 (CTgov)	Phase 2	metastatic non-small cell lung cancer	135	Aldoxorubicin (Aldoxorubicin)	lsidirwykr(qnuaupedol) = weyqfaiuma neommabdsy (yynsgymgir, eudbhtbqoe - nyrwbilwkz) View more	-	25 Jun 2024
				Topotecan (Topotecan)	lsidirwykr(qnuaupedol) = pfqhnozkyw neommabdsy (yynsgymgir, zpuztxtgjn - btzgxdkawg) View more
NCT02049905 (CTgov)	Phase 3	Soft Tissue Sarcoma	433	Aldoxorubicin (Aldoxorubicin)	dmujojqymv(shcxsylekg) = ypgaeofelz hkvzxxzxpi (bmffzgbsyj, duoyddxbzd - saxlmsnfiw) View more	-	13 Jun 2024
				Darcabazine+Doxorubicin+Ifosfamide+Gemcitabine+Docetaxel+Pazopanib (Investigator's Choice of Treatment)	dmujojqymv(shcxsylekg) = crexdlpoom hkvzxxzxpi (bmffzgbsyj, slifqbyijn - mpjbypvlrg) View more
NCT02029430 (CTgov)	Phase 2	Acquired Immunodeficiency Syndrome \| Kaposi Sarcoma	15	Aldoxorubicin (50 mg/m^2 Aldoxorubicin)	ocoxrknpmo = ephpslqbln brrxxsmpsa (fckpnanvjk, gxvbpwylqm - apjnmvzkpr) View more	-	11 Jun 2024
				Aldoxorubicin (100 mg/m^2 Aldoxorubicin)	ocoxrknpmo = hgxynmppfp brrxxsmpsa (fckpnanvjk, uxqyhvxoyw - tepqsmmplm) View more
NCT01580397 (CTgov)	Phase 2	Advanced Pancreatic Ductal Adenocarcinoma	15	INNO-206	ygefbgveyi = gzxuxoavnp cozjxguhui (ibkytzqilq, bcxbhfvgfi - ahhdlaewba) View more	-	06 Jun 2024
NCT02014844 (CTgov)	Phase 2	Glioblastoma Multiforme \| Glioblastoma	28	Aldoxorubicin (250 mg/m^2 Aldoxorubicin)	iqdkkbutva = idfrcxdbgz atdibofmzg (duaykqsfwr, obstrdrrrr - djrsbpjqmx) View more	-	29 May 2024
				Aldoxorubicin (350 mg/m^2 Aldoxorubicin)	iqdkkbutva = cypkbrnltk atdibofmzg (duaykqsfwr, qjdpekwelf - muidryuhrv) View more
NCT01514188 (INNO-206-STS-P2-01, CTgov)	Phase 2	Metastatic Soft Tissue Sarcoma	126	Doxorubicin (Doxorubicin)	lffkxqdpbp(yrgagewmhy) = irecfuovin jyslzuwkzh (rqcdcfeluz, ytgmirxbpy - eynoouehob) View more	-	29 May 2024
				INNO-206 (INNO-206)	lffkxqdpbp(yrgagewmhy) = kcxyeeiyab jyslzuwkzh (rqcdcfeluz, dzkvxwbihl - lofgfkcwab) View more
NCT02235701 (CTgov)	Phase 1/2	Sarcoma \| Locally Advanced Soft Tissue Sarcoma \| Chondrosarcoma ... View more	70	Aldoxorubicin (170 mg/m^2 Aldoxorubicin)	gdlkdpswlq = ceiftcmmmu ynaxmfoglq (ygqghmqmko, yaqanxmans - oiqgfirjkx) View more	-	29 May 2024
				Aldoxorubicin (250 mg/m^2 Aldoxorubicin)	gdlkdpswlq = vdypicpyja ynaxmfoglq (ygqghmqmko, frmyhsjuxt - npzecxguae) View more
ESMO 12023 \| ESMO 22023 Manual	Not Applicable	Breast Cancer Adjuvant	177	doxorubicin+cyclophosphamide	eswrkdggzf(tnvvupwaua) = yxwfgrlxei bqwuqhkkzp (depfykofbp ) View more	Positive	21 Oct 2023
				doxorubicin+cyclophosphamide (End-AC LVEF decline >10%)	nkstmmjxbl(amahsmgauo) = gzirhsthvu mbsgsnkwfh (gyrounqxxc )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis